Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Non-melanoma skin cancer (NMSC) is the most common form of cancer in the Caucasian population. Among NMSC types, basal cell carcinoma (BCC) has the highest incidence and squamous cell carcinoma (SCC) is less common although it can metastasize, accounting for the majority of NMSC-related deaths. Treatment options for NMSC include both surgical and non-surgical modalities. Even though surgical approaches are most commonly used to treat these lesions, Photodynamic Therapy (PDT) has the advantage of being a non-invasive option, and capable of field treatment, providing optimum cosmetic outcomes. Numerous clinical research studies have shown the efficacy of PDT for treating pre-malignant and malignant NMSC. However, resistant or recurrent tumors appear and sometimes become more aggressive. In this sense, the enhancement of PDT effectiveness by combining it with other therapeutic modalities has become an interesting field in NMSC research. Depending on the characteristics and the type of tumor, PDT can be applied in combination with immunomodulatory (Imiquimod) and chemotherapeutic (5-fluorouracil, methotrexate, diclofenac, or ingenol mebutate) agents, inhibitors of some molecules implicated in the carcinogenic process (COX2 or MAPK), surgical techniques, or even radiotherapy. These new strategies open the way to a wider improvement of the prevention and eradication of skin cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“The activation of these oxidative stress genes could contribute to a poor response to the treatment [69,70].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“Chemotherapy success is associated with factors related to the access of drugs to subcellular sites, cell-cycle kinetics and/or mutations [60–64].”
BackgroundMorton, C. A., Szeimies, R. ‐., Sidoroff, A., & Braathen, L. R. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12031 · Cited by 344
Rhodes, L. E., de Rie, M. A., Leifsdottir, R., Yu, R. C., Bachmann, I., Goulden, V., Wong, G. A. E., Richard, M.-A., Anstey, A., & Wolf, P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.9.1131 · Cited by 275 · cited 1×
“However, there are more studies supporting that tumor diameter does not affect the outcome [46–50].”
BackgroundThe UV response of the skin: a review of the MAPK, NFκB and TNFα signal transduction pathways
Muthusamy, V., & Piva, T. J. (2010) · Archives of Dermatological Research · doi:10.1007/s00403-009-0994-y · Cited by 265
Szeimies, R., Ibbotson, S., Murrell, D., Rubel, D., Frambach, Y., De Berker, D., Dummer, R., Kerrouche, N., Villemagne, H., & on behalf of the Excilight Study Group (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02803.x · Cited by 247
Vinciullo, C., Elliott, T., Francis, D., Gebauer, K., Spelman, L., Nguyen, R., Weightman, W., Sheridan, A., Reid, C., Czarnecki, D., et al. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06484.x · Cited by 158 · cited 1×
“If the tumor is present in the H zone of the face, regardless of size, the response is also reduced; considering also that this is a risk zone for BCC, PDT is not indicated in this area [48].”
BackgroundGuidelines for practical use of MAL‐PDT in non‐melanoma skin cancer
Christensen, E., Warloe, T., Kroon, S., Funk, J., Helsing, P., Soler, A., Stang, H., Vatne, Ø., & Mørk, C. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03430.x · Cited by 120 · cited 1×
“The use of keratolytic agents or curettage before PDT is mandatory for a successful PDT [28].”
BackgroundPhotodynamic therapy for basal cell carcinoma: Clinical and pathological determinants of response
Fantini, F., Greco, A., Del Giovane, C., Cesinaro, A. M., Venturini, M., Zane, C., Surrenti, T., Peris, K., & Calzavara‐Pinton, P. G. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03877.x · Cited by 113 · cited 1×
“However, there are more studies supporting that tumor diameter does not affect the outcome [46–50].”
BackgroundMüller-Decker, K. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9306-z · Cited by 73 · cited 1×
“In the same way, the overexpression of COX-2 in NMSC has been described and can be considered as an early marker of actinic damage in carcinogenesis [72,73].”
Background
Cited by
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholt, L., Seguin, N. B., Bataille, V., Marmol, V. D., Dummer, R., Harwood, C. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.003 · Cited by 599
Lebbe, C., Becker, J. C., Grob, J.-J., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Saiag, P., Middleton, M. R., Bastholt, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.131 · Cited by 500
Aggregation-Induced Emission (AIE), Life and Health
Wang, H., Li, Q., Alam, P., Bai, H., Bhalla, V., Bryce, M. R., Cao, M., Chen, C., Chen, S., Chen, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03925 · Cited by 385
Nanoparticle-based drug delivery systems for controllable photodynamic cancer therapy
Zheng, Y., Li, Z., Chen, H., & Gao, Y. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105213 · Cited by 370
Peris, K., Fargnoli, M. C., Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113254 · Cited by 308
Photodynamic Therapy: A Compendium of Latest Reviews
Algorri, J. F., Ochoa, M., Roldán-Varona, P., Rodríguez-Cobo, L., & López-Higuera, J. M. (2021) · Cancers · doi:10.3390/cancers13174447 · Cited by 263
Photodynamic Therapy and Non-Melanoma Skin Cancer
Griffin, L., & Lear, J. (2016) · Cancers · doi:10.3390/cancers8100098 · Cited by 81
“include cryotherapy, topical immunomodulation, laser and PDT [51].”
BackgroundPhotodynamic therapy: A hot topic in dermato-oncology (Review)
Tampa, M., Sarbu, M.-I., Matei, C., Mitran, C.-I., Mitran, M.-I., Caruntu, C., Constantin, C., Neagu, M., & Georgescu, S.-R. (2019) · Oncology Letters · doi:10.3892/ol.2019.9939 · Cited by 72
Gómez, C., Cobos, P., & Alberdi, E. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102176 · Cited by 12
Metadata
- Authors
- Lucena, S., Salazar, N., Gracia-Cazaña, T., Zamarrón, A., González, S., Juarranz, Á., & Gilaberte, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-10-28
- Volume
- 16
- Issue
- 10
- Pages
- 25912-25933
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W1899126153
- Cited by
- 142
- References
- 11
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.